Granite Investment Partners LLC Acquires New Stake in Halozyme Therapeutics, Inc. (HALO)
Granite Investment Partners LLC acquired a new stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO) during the second quarter, Holdings Channel reports. The fund acquired 565,507 shares of the biopharmaceutical company’s stock, valued at approximately $7,250,000.
Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Ameritas Investment Partners Inc. purchased a new position in Halozyme Therapeutics during the first quarter valued at $122,000. Karp Capital Management Corp purchased a new position in Halozyme Therapeutics during the first quarter valued at $188,000. Stifel Financial Corp purchased a new position in Halozyme Therapeutics during the first quarter valued at $187,000. IFP Advisors Inc boosted its position in Halozyme Therapeutics by 1.6% in the second quarter. IFP Advisors Inc now owns 14,686 shares of the biopharmaceutical company’s stock valued at $188,000 after buying an additional 226 shares during the last quarter. Finally, Parametrica Management Ltd purchased a new position in Halozyme Therapeutics during the first quarter valued at $212,000. Hedge funds and other institutional investors own 81.49% of the company’s stock.
Halozyme Therapeutics, Inc. (HALO) opened at 12.13 on Friday. The company has a 50 day moving average price of $13.21 and a 200-day moving average price of $13.11. Halozyme Therapeutics, Inc. has a 12 month low of $8.18 and a 12 month high of $15.20. The company’s market cap is $1.72 billion.
Halozyme Therapeutics (NASDAQ:HALO) last issued its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($0.23) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.25) by $0.02. The company had revenue of $33.80 million for the quarter, compared to analysts’ expectations of $31.76 million. The business’s revenue for the quarter was up 1.2% on a year-over-year basis. During the same period last year, the company posted ($0.21) EPS. Equities analysts predict that Halozyme Therapeutics, Inc. will post ($0.97) earnings per share for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: “Granite Investment Partners LLC Acquires New Stake in Halozyme Therapeutics, Inc. (HALO)” was first published by Watch List News and is owned by of Watch List News. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of United States and international copyright & trademark legislation. The original version of this news story can be viewed at https://www.watchlistnews.com/granite-investment-partners-llc-acquires-new-stake-in-halozyme-therapeutics-inc-halo/1473833.html.
Several research analysts have weighed in on the company. Piper Jaffray Companies set a $20.00 price objective on Halozyme Therapeutics and gave the stock a “buy” rating in a research report on Thursday. Jefferies Group LLC reiterated an “underperform” rating and set a $7.00 price objective (up previously from $6.75) on shares of Halozyme Therapeutics in a research report on Thursday. Canaccord Genuity set a $16.00 price objective on Halozyme Therapeutics and gave the stock a “buy” rating in a research report on Wednesday, July 26th. BidaskClub cut Halozyme Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, July 1st. Finally, ValuEngine upgraded Halozyme Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, June 2nd. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and five have given a buy rating to the company. Halozyme Therapeutics currently has an average rating of “Hold” and a consensus price target of $14.88.
Halozyme Therapeutics Company Profile
Halozyme Therapeutics, Inc is a biotechnology company focused on developing and commercializing oncology therapies. The Company operates in research, development and commercialization of human enzymes and other drug candidates. The Company’s segment also includes research and development activities and product sales of Hylenex recombinant.
Want to see what other hedge funds are holding HALO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Halozyme Therapeutics, Inc. (NASDAQ:HALO).
Receive News & Ratings for Halozyme Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.